Detail akcie Exicure Rg online

Business Summary: Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company, through GPCR Therapeutics USA Inc. (GPCR USA), is focused on developing and commercializing an intellectual property and patents related to G-Protein Coupled Receptors. GPCR USA is conducting a Phase II clinical trial for a blood cancer treatment involving GPC-100 (Burixafor). The Company is also exploring strategic alternatives to maximize stockholder value.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Exicure Inc revenues decreased from $500K to $0K. Net loss decreased 19% to $2M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research & Development based on SNA technology segment loss decrease of 24% to $2M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.40 to -$0.31.